A blue check for Sputnik V—and a cautionary marketing tale for the pharma industry? The Russian-developed coronavirus vaccine nabbed verified status from Twitter last week, doubling down on its broadcasting wave of tweets, retweets and plenty of American-style attitude.
But is the now-authenticated social media account a pharma influencer case study or a cautionary tale of disinformation?
While the account’s relaxed tone may offer some lightening-up lessons for pharma, the Sputnik V public relations push is also implicated in a newly revealed Russian disinformation campaign to propel vaccine sales.
Author: Canan Schuman, PharmD/PhD
Canan Schumann is Chief Editor for Axxiem and for Axxiem's blog "BiotechOntheWeb". When not writing for Axxiem, Canan works as a Clinical Research Scientist II at the Research and Development Department at Molecular Testing Labs, developing endpoint assays for the detection of infectious disease and cancer. Canan currently resides in Portland, Oregon, where he received his Honors Bachelor of Science (HBS), Doctor of Pharmacy (PharmD.), and his Doctor of Philosophy (Ph.D.) in Biopharmaceutics at Oregon State University.